semantico
delivering online publishing solutions

Four interesting examples ...

... of how technology developments support new business models.

Richard Padley, Managing Director, Semantico.

Good morning. I'd like to share ...

Example #1 is about Researchers. Specifically its about focus on researcher needs. It starts with a piece of researcher focussed technology that creates some interesting opportunities.

Example #1 is about Researchers. Specifically its about focus on researcher needs. It starts with a piece of researcher focussed technology that creates some interesting opportunities.

semantico

ORCID Open Researcher & Contributor ID

Home My Researcher Profile Refer a Colleague Logout Search

Personal Information | My Affiliations | Password | Options | Return to My Researcher Profile

Update your information. Optionally, use the "public" setting to indicate which information to display on your Profile page. Clear a public check box to make that information private. Note: Click the "Submit Changes" button on each page. * required fields.

Submit Changes on this Page | Cancel

☑ Public (Master)	First / Given Name:	Martin *	**Public (Master):** Clear the "Public (Master)" check box to make your information private. Only you, when logged in, will be able to view your information.
	Last / Family Name:	Fenner *	**Name:** Your name will be searched and displayed on your profile page.
	Middle Initials:	H	
	ORCID ID:	AAA-1034-2010	**ORCID ID:** This is your unique identification.
☑ Public	Other Names Used by You:	Add / Remove	**Other Names:** If you've published under different names or if you are known by more than one name, enter Other Names. These will be searched if made public.
☑ Public	URL:	http://www.orcidsandbox.org/rid/AAA-1034-2010	**URL:** The URL can be used to link directly to your profile page.

Who's heard about ORCID? You may not know its being developed by Semantico. Socially validated platform for Discovery, Attribution, & Disambiguation in the scholarly record. Stakeholders are Researchers, libraries, funding agencies, & Publishers. Many important consequences will follow; facilitates calculation of more sophisticated measures of impact – author metrics – e.g. h-index











Monday, 23 April 12

WIll feed into Altmetrics phenomenon. Triangulation rather than single measure of impact.
Tech: Big data, firehose, hadoop, NoSQL datastores, API level integration.
SAAS business model. Returning to h-index is …



Who's seen this? Google scholar metrics, launched 1 April. This is no joke. H-index. Another elephant in the room is the biggest business model shift ...

Researcher focussed business model. Publishing sold is a service, not a physical good, or a licence to access IP. Paraphrase Ahmed Hindawi: increased competition, differentiation around the service. OA raises the bar. Service is for authors; differentiation in adding value for authors.

Example #2 User Generated Content. RMM in print until 7e; but often supplemented with local notes and modifications. Tech: Flexible XML content database for R/W content. Allows seamless presentation of published & UGC. Like a Wiki BUT private to each subscribing institution. Audit trail. Innovation is delivering Content in Context for clinical practitioners, rather than bus model.



Example #3

Business Goals 1: Drive subscriber usage, 2: Reach a new market with new model - day pass

SEO project for CABI. 1.5M abstracts

swine as models in biomedical research - Google Search

http://www.google.com/search?client=safari&rls=en&q=theory+site:cabdirect.org&ie=UTF-8

theory site:cabdirect.org

Salesforce GApps Calendar Semantico Ideas Board Corporate Basecamp National Rail

+You **Search** Images Videos Maps News Shopping Mail More richardp@gapps.semantico.com

Google swine as models in biomedical research

Search About 229,000 results (0.24 seconds)

Everything
Images
Maps
Videos
News
Shopping
More

All results
Related searches

More search tools

Scholarly articles for swine as models in biomedical research
Swine as models in biomedical research. - Swindle - Cited by 74
Advances in **swine** in **biomedical research** - Tumbleson - Cited by 187
Swine as models in experimental surgery - Swindle - Cited by 119

Amazon.com: Swine as Models in Biomedical Research ...
www.amazon.com › ... › Medical Books › Medicine › Internal Medicine
"**Swine as Models in Biomedical Research**" is based on the proceedings of the Seventh Charles River International Symposium, which called upon recognised ...

Swine as Models in Biomedical Research and Toxicology Testing
vet.sagepub.com/content/early/2011/.../0300985811402846.abstract?...
by MM Swindle - 2011 - Cited by 6 - Related articles
25 Mar 2011 – **Swine** are considered to be one of the major animal species used in translational **research**, surgical models, and procedural training and are ...

Swine as models in biomedical research. - CAB Direct
cabdirect.org/abstracts/19942200241.html?start=450
by MM Swindle - 1992 - Cited by 74 - Related articles
Abstract. The Seventh Charles River International Symposium was held at Danvers, Massachusetts in September 1989. 18 symposium contributions deal with ...

srb94-01
www.nal.usda.gov/awic/pubs/oldbib/srb94-01.htm
Swine have been utilized as a biomedical research model in a wide variety of disciplines; the ... **Swine as Models in Biomedical Research** M.M. Swindle, D.C.

Example #3
Business Goals 1: Drive subscriber usage, 2: Reach a new market with new model – day pass
SEO project for CABI. 1.5M abstracts



Monday, 23 April 12

CAB instant access; also Google Ad revenue

Visitors Overview

100.00% of total visits

Overview



Visits increased 1200 to 36,000 (+3000%); Subscriber visits to 5000 (+400%)

Visitors Overview

Jan 1, 2011 - Apr 17, 2012

100.00% of total visits

Overview



4,009,481 people visited this site

Not SEO - Politics & Google making up the rules as they go along.

Example #4. Data mining. Sydney Brenner: "Data mining means my data are mine, and your data are mine, too."

Improve UX, Increase discoverability, stickiness - lower cost/download. Slice/dice to create new products. Lower production costs, improve consistency, time to market. Parsing whole sentances, sentiment, citation typing. >equiv terms >search >medical. Large scale meta-analyses (Pharma). Highly targeted advertising:

Utopia Documents – The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications

OPEN ACCESS Freely available online PLoS COMPUTATIONAL BIOLOGY

The *Mycobacterium tuberculosis* Drugome and Its Polypharmacological Implications

Sarah L. Kinnings[1,2], Li Xie[3], Kingston H. Fung[4], Richard M. Jackson[1], Lei Xie[3]*, Philip E. Bourne[2,3]*

1 Institute of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, United Kingdom, 2 San Diego Supercomputer Center, University of California, San Diego, La Jolla, California, United States of America, 3 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, United States of America, 4 Bioinformatics Program, University of California, San Diego, La Jolla, California, United States of America

Abstract

We report a computational approach that integrates structural bioinformatics, molecular modelling and systems biology to construct a drug-target network on a structural proteome-wide scale. The approach has been applied to the genome of *Mycobacterium tuberculosis* (*M.tb*), the causative agent of one of today's most widely spread infectious diseases. The resulting drug-target interaction network for all structurally characterized approved drugs bound to putative *M.tb* receptors, we refer to as the 'TB-drugome'. The TB-drugome reveals that approximately one-third of the drugs examined have the potential to be repositioned to treat tuberculosis and that many currently unexploited *M.tb* receptors may be chemically druggable and could serve as novel anti-tubercular targets. Furthermore, a detailed analysis of the TB-drugome has shed new light on the controversial issues surrounding drug-target networks [1–3]. Indeed, our results support the idea that drug-target networks are inherently modular, and further that any observed randomness is mainly caused by biased target coverage. The TB-drugome (http://funsite.sdsc.edu/drugome/TB) has the potential to be a valuable resource in the development of safe and efficient anti-tubercular drugs. More generally the methodology may be applied to other pathogens of interest with results improving as more of their structural proteomes are determined through the continued efforts of structural biology/genomics.

Citation: Kinnings SL, Xie L, Fung KH, Jackson RM, Xie L, et al. (2010) The *Mycobacterium tuberculosis* Drugome and Its Polypharmacological Implications. PLoS Comput Biol 6(11): e1000976. doi:10.1371/journal.pcbi.1000976

Editor: Ruth Nussinov, National Cancer Institute, United States of America and Tel Aviv University, Israel

Received July 8, 2010; **Accepted** September 24, 2010; **Published** November 4, 2010

Funding: This research is funded by National Institutes of Health grant GM078396 (http://www.nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lxie@ucsd.edu (LX); pbourne@ucsd.edu (PEB)

Introduction

The construction and analysis of molecular interaction networks provides a powerful means to understand the complexity of biological systems and to reveal hidden relationships between drugs, genes, proteins, and diseases. In particular, the study of drug-target networks may facilitate an improved understanding of the principles of polypharmacology and hence improved rational drug design [2]. In recent years, several computational methodologies have been developed to predict drug-target networks based on ligand chemistry [4–6], phenotypic changes resulting from drug perturbation [7–9], or a combination of chemical features of drugs and sequence features of protein targets [10–12]. Extensive experimental and computational evaluation has proven that these methods are valuable for drug repurposing and side effect prediction. However, these methods are biased towards known drug-target pairs, which are mainly derived from well-established human target classes such as G-protein coupled receptors (GPCRs), which only cover a small portion of the human proteome. The lack of a broad spectrum of drug-target pairs is more severe in pathogens than it is in human. For example, amongst the 3,999 proteins encoded by the *Mycobacterium tuberculosis* (*M.tb*) genome, only nine (cmaA1, cyp51, embA, embB, embC, folK, InhA, katG and rpoC) have been pharmaceutically investigated [13]. Thus, drug-target networks that are constructed from only existing drug targets are retrospective, and less capable of discovering new druggable targets and predicting off-target profiles of new compounds on a proteome-wide scale. In addition, the incompleteness of drug-target data poses questions as to whether or not the topology of drug-target networks is inherently modular or random [1].

It is important to construct and analyze a proteome-wide drug-target network that includes not only the primary targets, but also all of the potential off-targets of the drugs in the network. Such a network, if available, would provide unparalleled opportunities for mapping a comprehensive drug-target space and understanding the molecular basis of drug efficacy, side- effects and drug resistance, thereby providing the foundation for the rational design of polypharmacological (multi-target) drugs. For anti-infectious drug discovery, where pharmaceutically investigated targets only represent a small portion of the whole pathogen's proteome, it is more challenging to establish a proteome-wide drug-target network. The linkage of drugs to less exploited proteins such as virulence factors, transport proteins and transcription factors will greatly expand the repository of anti-infectious drug targets and provide new solutions for combating multi-drug and extensively drug resistant pathogens, and for repurposing existing drugs for new uses.

Structural bioinformatics provides an alternative and complementary way to extend drug-target networks to less characterized proteins on a proteome-wide scale. The structural coverage of a given pathogen proteome is usually much larger than the

Back — Mycobacterium tuberculosis

Wikipedia entries
Community curated encyclopedia entries

Protein Data Bank structures
Biological macromolecular structures

Articles from PubMed
Related recent articles

SciBite
Biomedical News & Intelligence

For the lab
Related laboratory resources

▼ **Mycobacterium tuberculosis**

Supplier	Novus Biologicals
Host organism	Mouse
Reactivity	Bacteria
Clonality	Monoclonal
Volume	0.2mg

Application	ELISA	Details...
Application	ELISA	Details...
Application	ELISA, Western Blot	Details...

- ▶ anti-Mycobacterium Tuberculosis (16 kDa Ag) antibody
- ▶ anti-Mycobacterium tuberculosis (38 kDa Ag) antibody
- ▶ anti-Mycobacterium tuberculosis (all gens) antibody (Biotin)
- ▶ Mycobacterium Tuberculosis
- ▶ MYCOBACTERIUM TUBERCULOSIS Recombinant Protein
- ▶ anti-Mycobacterium tuberculosis (all gens) antibody
- ▶ anti-Mycobacterium tuberculosis Hsp65 antibody
- ▶ RABBIT ANTI MYCOBACTERIUM TUBERCULOSIS Antibody (1ml)
- ▶ DnaK Mycobacterium Tuberculosis

Monday, 23 April 12

Utopia documents.
Mycobacterium Tuberculosis. “For the lab”. Micro-advertising. Jan Velterop – AQnowledge provides this to Utopia.

Utopia Documents – The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications

OPEN ACCESS Freely available online PLoS COMPUTATIONAL BIOLOGY

The *Mycobacterium tuberculosis* Drugome and Its Polypharmacological Implications

Sarah L. Kinnings[1,2], Li Xie[3], Kingston H. Fung[4], Richard M. Jackson[1], Lei Xie[3]*, Philip E. Bourne[2,3]*

1 Institute of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, United Kingdom, 2 San Diego Supercomputer Center, University of California, San Diego, La Jolla, California, United States of America, 3 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, United States of America, 4 Bioinformatics Program, University of California, San Diego, La Jolla, California, United States of America

Abstract

We report a computational approach that integrates structural bioinformatics, molecular modelling and systems biology to construct a drug-target network on a structural proteome-wide scale. The approach has been applied to the genome of *Mycobacterium tuberculosis* (*M.tb*), the causative agent of one of today's most widely spread infectious diseases. The resulting drug-target interaction network for all structurally characterized approved drugs bound to putative *M.tb* receptors, we refer to as the 'TB-drugome'. The TB-drugome reveals that approximately one-third of the drugs examined have the potential to be repositioned to treat tuberculosis and that many currently unexploited *M.tb* receptors may be chemically druggable and could serve as novel anti-tubercular targets. Furthermore, a detailed analysis of the TB-drugome has shed new light on the controversial issues surrounding drug-target networks [1–3]. Indeed, our results support the idea that drug-target networks are inherently modular, and further that any observed randomness is mainly caused by biased target coverage. The TB-drugome (http://funsite.sdsc.edu/drugome/TB) has the potential to be a valuable resource in the development of safe and efficient anti-tubercular drugs. More generally the methodology may be applied to other pathogens of interest with results improving as more of their structural proteomes are determined through the continued efforts of structural biology/genomics.

Citation: Kinnings SL, Xie L, Fung KH, Jackson RM, Xie L, et al. (2010) The *Mycobacterium tuberculosis* Drugome and Its Polypharmacological Implications. PLoS Comput Biol 6(11): e1000976. doi:10.1371/journal.pcbi.1000976

Editor: Ruth Nussinov, National Cancer Institute, United States of America and Tel Aviv University, Israel

Received July 8, 2010; **Accepted** September 24, 2010; **Published** November 4, 2010

Funding: This research is funded by National Institutes of Health grant GM078396 (http://www.nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lxie@ucsd.edu (LX); pbourne@ucsd.edu (PEB)

Introduction

The construction and analysis of molecular interaction networks provides a powerful means to understand the complexity of biological systems and to reveal hidden relationships between drugs, genes, proteins, and diseases. In particular, the study of drug-target networks may facilitate an improved understanding of the principles of polypharmacology and hence improved rational drug design [2]. In recent years, several computational methodologies have been developed to predict drug-target networks based on ligand chemistry [4–6], phenotypic changes resulting from drug perturbation [7–9], or a combination of chemical features of drugs and sequence features of protein targets [10–12]. Extensive experimental and computational evaluation has proven that these methods are valuable for drug repurposing and side effect prediction. However, these methods are biased towards known drug-target pairs, which are mainly derived from well-established human target classes such as G-protein coupled receptors (GPCRs), which only cover a small portion of the human proteome. The lack of [illegible] drug-target pairs is [illegible] in pathogens than it is in human. For example, amongst the 3,999 proteins encoded by the *Mycobacterium tuberculosis* (*M.tb*) genome, only nine (cmaA1, cyp51, embA, embB, [illegible], folK, InhA, katG and rpoC) have been pharmacologically investigated [13] [illegible] are constructed from only existing drug targets are retrospective, and less capable of discovering new druggable targets and predicting off-target profiles of new compounds on a proteome-wide scale. In addition, the incompleteness of drug-target data poses questions as to whether or not the topology of drug-target networks is inherently modular or random [1].

It is important to construct and analyze a proteome-wide drug-target network that includes not only the primary targets, but also all of the potential off-targets of the drugs in the network. Such a network, if available, would provide unparalleled opportunities for mapping a comprehensive drug-target space and understanding the molecular basis of drug efficacy, side- effects and drug resistance, thereby providing the foundation for the rational design of polypharmacological (multi-target) drugs. For anti-infectious drug discovery, where pharmaceutically investigated targets only represent a small portion of the whole pathogen's proteome, it is more challenging to establish a proteome-wide drug-target network. The linkage of drugs to less exploited proteins such as virulence factors, transport proteins and transcription factors will greatly expand the repository of anti-infectious drug targets and provide new solutions for combating multi-drug and extensively drug resistant pathogens, and for repurposing existing drugs for [illegible] uses.

Structural bioinformatics provides an alternative and complementary way to extend drug-target networks to less characterized proteins on a proteome-wide scale. The structural coverage of a given pathogen proteome is usually much larger than the

Back — Mycobacterium tuberculosis

Wikipedia entries
Community curated encyclopedia entries

Protein Data Bank structures
Biological macromolecular structures

Articles from PubMed
Related recent articles

SciBite
Biomedical News & Intelligence

For the lab
Related laboratory resources

▼ **Mycobacterium tuberculosis**

Supplier	Novus Biologicals
Host organism	Mouse
Reactivity	Bacteria
Clonality	Monoclonal
Volume	0.2mg
Application	ELISA — Details...
Application	ELISA — Details...
Application	ELISA, Western Blot — Details...

- ▶ anti-Mycobacterium Tuberculosis (16 kDa Ag) antibody
- ▶ anti-Mycobacterium tuberculosis (38 kDa Ag) antibody
- ▶ anti-Mycobacterium tuberculosis (all gens) antibody (Biotin)
- ▶ Mycobacterium Tuberculosis
- ▶ MYCOBACTERIUM TUBERCULOSIS Recombinant Protein
- ▶ anti-Mycobacterium tuberculosis (all gens) antibody
- ▶ anti-Mycobacterium tuberculosis Hsp65 antibody
- ▶ RABBIT ANTI MYCOBACTERIUM TUBERCULOSIS Antibody (1ml)
- ▶ DnaK Mycobacterium Tuberculosis

Monday, 23 April 12

Utopia documents.
Mycobacterium Tuberculosis. “For the lab”. Micro-advertising. Jan Velterop – AQnowledge provides this to Utopia.

Utopia Documents – The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications

OPEN ACCESS Freely available online

PLoS COMPUTATIONAL BIOLOGY

The *Mycobacterium tuberculosis* Drugome and Its Polypharmacological Implications

Sarah L. Kinnings[1,2], Li Xie[3], Kingston H. Fung[4], Richard M. Jackson[1], Lei Xie[3]*, Philip E. Bourne[2,3]*

1 Institute of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, United Kingdom, 2 San Diego Supercomputer Center, University of California, San Diego, La Jolla, California, United States of America, 3 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, United States of America, 4 Bioinformatics Program, University of California, San Diego, La Jolla, California, United States of America

Abstract

We report a computational approach that integrates structural bioinformatics, molecular modelling and systems biology to construct a drug-target network on a structural proteome-wide scale. The approach has been applied to the genome of *Mycobacterium tuberculosis* (*M.tb*), the causative agent of one of today's most widely spread infectious diseases. The resulting drug-target interaction network for all structurally characterized approved drugs bound to putative *M.tb* receptors, we refer to as the 'TB-drugome'. The TB-drugome reveals that approximately one-third of the drugs examined have the potential to be repositioned to treat tuberculosis and that many currently unexploited *M.tb* receptors may be chemically druggable and could serve as novel anti-tubercular targets. Furthermore, a detailed analysis of the TB-drugome has shed new light on the controversial issues surrounding drug-target networks [1–3]. Indeed, our results support the idea that drug-target networks are inherently modular, and further that any observed randomness is mainly caused by biased target coverage. The TB-drugome (http://funsite.sdsc.edu/drugome/TB) has the potential to be a valuable resource in the development of safe and efficient anti-tubercular drugs. More generally the methodology may be applied to other pathogens of interest with results improving as more of their structural proteomes are determined through the continued efforts of structural biology/genomics.

Citation: Kinnings SL, Xie L, Fung KH, Jackson RM, Xie L, et al. (2010) The *Mycobacterium tuberculosis* Drugome and Its Polypharmacological Implications. PLoS Comput Biol 6(11): e1000976. doi:10.1371/journal.pcbi.1000976

Editor: Ruth Nussinov, National Cancer Institute, United States of America and Tel Aviv University, Israel

Received July 8, 2010; **Accepted** September 24, 2010; **Published** November 4, 2010

Funding: This research is funded by National Institutes of Health grant GM078396 (http://www.nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lxie@ucsd.edu (LX); pbourne@ucsd.edu (PEB)

Introduction

The construction and analysis of molecular interaction networks provides a powerful means to understand the complexity of biological systems and to reveal hidden relationships between drugs, genes, proteins, and diseases. In particular, the study of drug-target networks may facilitate an improved understanding of the principles of polypharmacology and hence improved rational drug design [2]. In recent years, several computational methodologies have been developed to predict drug-target networks based on ligand chemistry [4–6], phenotypic changes resulting from drug perturbation [7–9], or a combination of chemical features of drugs and sequence features of protein targets [10–12]. Extensive experimental and computational evaluation has proven that these methods are valuable for drug repurposing and side effect prediction. However, these methods are biased towards known drug-target pairs, which are mainly derived from well-established human target classes such as G-protein coupled receptors (GPCRs), which only cover a small portion of the human proteome. The lack of a broad spectrum of drug-target pairs is more severe in pathogens than it is in human. For example, amongst the 3,999 proteins encoded by the *Mycobacterium tuberculosis* (*M.tb*) genome, only nine (cmaA1, cyp51, embA, embB, embC, folK, InhA, katG and rpoC) have been pharmaceutically investigated [13]. Thus, drug-target networks that are constructed from only existing drug targets are retrospective, and less capable of discovering new druggable targets and predicting off-target profiles of new compounds on a proteome-wide scale. In addition, the incompleteness of drug-target data poses questions as to whether or not the topology of drug-target networks is inherently modular or random [1].

It is important to construct and analyze a proteome-wide drug-target network that includes not only the primary targets, but also all of the potential off-targets of the drugs in the network. Such a network, if available, would provide unparalleled opportunities for mapping a comprehensive drug-target space and understanding the molecular basis of drug efficacy, side- effects and drug resistance, thereby providing the foundation for the rational design of polypharmacological (multi-target) drugs. For anti-infectious drug discovery, where pharmaceutically investigated targets only represent a small portion of the whole pathogen's proteome, it is more challenging to establish a proteome-wide drug-target network. The linkage of drugs to less exploited proteins such as virulence factors, transport proteins and transcription factors will greatly expand the repository of anti-infectious drug targets and provide new solutions for combating multi-drug and extensively drug resistant pathogens, and for repurposing existing drugs for new uses.

Structural bioinformatics provides an alternative and complementary way to extend drug-target networks to less characterized proteins on a proteome-wide scale. The structural coverage of a given pathogen proteome is usually much larger than the

Back — Mycobacterium tuberculosis

Wikipedia entries
Community curated encyclopedia entries

Protein Data Bank structures
Biological macromolecular structures

Articles from PubMed
Related recent articles

SciBite
Biomedical News & Intelligence

For the lab
Related laboratory resources

▼ **Mycobacterium tuberculosis**

Supplier	Novus Biologicals
Host organism	Mouse
Reactivity	Bacteria
Clonality	Monoclonal
Volume	0.2mg
Application	ELISA

Details...

Application	ELISA

Details...

Application	ELISA, Western Blot

Details...

- ▶ anti-Mycobacterium Tuberculosis (16 kDa Ag) antibody
- ▶ anti-Mycobacterium tuberculosis (38 kDa Ag) antibody
- ▶ anti-Mycobacterium tuberculosis (all gens) antibody (Biotin)
- ▶ Mycobacterium Tuberculosis
- ▶ MYCOBACTERIUM TUBERCULOSIS Recombinant Protein
- ▶ anti-Mycobacterium tuberculosis (all gens) antibody
- ▶ anti-Mycobacterium tuberculosis Hsp65 antibody
- ▶ RABBIT ANTI MYCOBACTERIUM TUBERCULOSIS Antibody (1ml)
- ▶ DnaK Mycobacterium Tuberculosis

Monday, 23 April 12

Utopia documents.
Mycobacterium Tuberculosis. “For the lab”. Micro-advertising. Jan Velterop - AQnowledge provides this to Utopia.



Interferon@nature.com

The page hosts a collection of interferon-related original research articles, reviews and commentaries published by the Nature Publishing Group. This list is updated automatically using smart search technology but is not intended to be exhaustive. If you are unable to find a paper of interest, please use the nature.com search.

Sign up for monthly newsletter to receive content updates.

Access to the free content is supported by PBL InterferonSource.

Highlighted articles

***In vivo* prevention of transplant arteriosclerosis by *ex vivo*–expanded human regulatory T cells** FREE
Satish N Nadig, Joanna Więckiewicz, Douglas C Wu, Gregor Warnecke, Wei Zhang, Shiqiao Luo, Alexandru Schiopu, David P Taggart, Kathryn J Wood
doi:10.1038/nm.2154
Nature Medicine

Full Text | PDF | Rights and permissions | Save this link

The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a β-catenin-dependent pathway FREE
Pengyuan Yang, Huazhang An, Xingguang Liu, Mingyue Wen, Yuanyuan Zheng, Yaocheng Rui, Xuetao Cao
doi:10.1038/ni.1876
Nature Immunology

Full Text | PDF | Rights and permissions | Save this link

Treatment of metastatic renal cell carcinoma FREE
Maxine Sun, Giovanni Lughezzani, Paul Perrotte, Pierre I. Karakiewicz
doi:10.1038/nrurol.2010.57
Nature Reviews Urology

Full Text | PDF | Rights and permissions | Save this link

miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator FREE
Dimitrios Lagos, Gabriel Pollara, Stephen Henderson, Fiona Gratrix, Martin Fabani, Richard S.B. Milne, Frances Gotch, Chris Boshoff
doi:10.1038/ncb2054
Nature Cell Biology

nature network

Latest from related *Nature Networks* discussions:

Infectious Disease: What Can Evolution Do For Us?

Immunology Forum

Mucosal Immunology Forum

$10,000 open innovation challenge to fight infectious diseases affecting 30 million people

More from *Nature Network*

naturejobs

Postdoctoral Position: Regulation of skeletal muscle metabolism and insulin resistance
The National Institutes of Health, The National Institute of Diabete, Digestive, and Kidney Disease
Bethesda, MD

Assistant Professor Level
University of Tennessee
Knoxville United States

More science jobs

Post a job for free

Monday, 23 April 12

Topic pages on nature.com
Powered by Luxid from Temis; categorising and semantic tagging.